These findings highlight the dual role of PD-1/PD-L1 in AD, suggesting systemic PD-1 blockade may offer therapeutic potential, while local PD-1 deficiency might exacerbate neuroinflammation and disease severity. Here, CD274 is linked to Alzheimer disease.